AML Hub

0:11:54

Should MRD negativity post remission impact treatment decisions in ELN-intermediate risk AML?

0:04:46

How can we improve efficacy of CAR T-cell therapy in AML?

0:01:46

Introducing AMLHUB: Your Anti Money Laundering Solution

0:03:51

What is the optimal prognostic threshold for MFC MRD positivity in patients with AML?

0:01:47

AML Hub (AML Global Portal): A note from the editor-in-chief

0:03:09

How to approach patients who are MRD positive after initial induction chemotherapy?

0:00:53

Charles Craddock explains why you should join the virtual AML Hub Satellite Symposium

0:06:21

What exciting updates on maintenance therapy in AML were presented at ASH 2023?

0:01:01

IMAGINATION #music #animals #facts #tieatie #kpop #iphonereview #howtoloseweight #yogaforbeginners

0:01:48

Gert Ossenkoppele explains why you should join the virtual AML Hub Satellite Symposium

0:01:45

Christian Thiede explains why you should join the virtual AML Hub Satellite Symposium

0:02:33

Highlights of the AML Hub Satellite Symposium

0:05:17

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

0:09:55

3rd AutomationML PlugFest: Engineering Data Management with the AML Hub

0:04:08

What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?

0:22:07

AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair

0:05:29

In the AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?

0:08:37

How can outcomes be improved in patients with molecularly-defined high-risk AML?

0:04:38

Menin inhibition in relapsed/refractory AML: what do the data tell us?

0:02:44

Does race affect treatment outcome in AML?

0:03:43

How does pretransplant 𝘐𝘋𝘏1 and 𝘐𝘋𝘏2 MRD affect posttransplant outcomes in patients with AML?

0:01:29

FLT3 mutations in AML

0:01:27

How can genetic studies inform the treatment of AML?

0:04:52

New classification of AML